Newmark (NMRK) Q2 2026 Earnings Call Transcript

Newmark reported Q2 2026 total revenues of $888.4M, up 17.0% year over year, and adjusted EPS of $0.39 (+25.8% YoY). Adjusted EBITDA rose 22.1% to $139.2M, with EBITDA margin up 65 bps, while trailing-12-month adjusted free cash flow increased 71.6% to $391.1M; the company also repurchased 10.4M shares for $151.1M in H1 2026 at an average $14.58. Management reaffirmed full-year 2026 guidance: revenue of $3.775B–$3.875B (+15% to +18%) and adjusted EPS of $1.87–$1.98 (+15% to +22%). Despite a tougher second-half comp, management cited a healthy transaction pipeline and AI as a long-term productivity driver, keeping confidence in double-digit growth.

Analysis

The core signal is not the quarter itself but the mix shift: recurring fee streams are now doing enough of the heavy lifting that NMRK is becoming less hostage to lumpy transaction timing. That should support multiple expansion if management can keep adding higher-quality, less cyclical revenue through M&A and cross-sell; the market will likely reward that more than one more quarter of headline volume growth. The near-term loser, if this persists, is the more transaction-dependent brokerage complex: firms with weaker recurring revenue and less share gain leverage will look like lower-quality duration exposure to CRE volumes.

The catch is cadence. The back half is the real test because last year’s comps were easier and the call implicitly says a few large deals can swing the print. That means the stock can stall for 4-8 weeks if investors focus on the unchanged guide, but the more important catalyst path is 1-3 months: transaction closings, any M&A announcement, and evidence that buybacks restart if deal pipeline slips. Over 6-18 months, the balance sheet and cash generation argue NMRK can keep taking share without stressing capital, but only if CRE rates stay stable and data-center / office-conversion activity keeps converting from pipeline to fees.

Contrarian view: consensus may be underestimating how much of this is self-help rather than beta. If management is right that mix, not just market recovery, is driving growth, then the multiple should move toward a higher-quality services platform, not a cyclical broker. The risk is that investors overpay for the narrative before volume normalization is proven; a single weak quarter in debt origination or delayed big-ticket deals would expose how much optimism is embedded. Falsifier: if 3Q/4Q revenue growth drops materially below low-teens or management stops talking about recurring revenue expansion and market-share gains, the re-rating case weakens fast.

Key Decisions for Investors

• Buy NMRK on post-earnings consolidation or any 3-5% pullback; target 3-6 months. Risk/reward is attractive if the market eventually prices the recurring-revenue mix shift rather than the unchanged guide.
• Pair trade: long NMRK / short CBRE or JLL for 3-6 months to isolate share-gain and mix-improvement upside versus more mature, less incremental operating leverage. Stop if NMRK loses share or if CRE volumes broadly reaccelerate without benefiting NMRK.
• If you want a lower-risk expression, sell cash-secured puts or use a bull call spread in NMRK into the next quarter, with the thesis that timing noise suppresses the stock while underlying fee growth remains intact.
• Add an alert on 3Q debt/origination volumes and any M&A announcement; if capital allocation shifts back to repurchases, that is a near-term positive catalyst for EPS and should support upside surprise in consensus.
• Do not chase if the stock rerates sharply on the print; wait for confirmation that back-half comps are clearing and that management converts pipeline into closed deals, otherwise the move is likely just a sentiment pop.